From discovery to prevention: the story behind aspirin and Lynch syndrome

9 hours ago
5 min read

At Lynch Syndrome UK, we're always keen to share not just the latest research, but the stories behind it. While we've covered the findings from the CaPP3 aspirin trial in previous posts, a recent episode of Genomics England's Behind the Genes podcast offers something different: an opportunity to hear directly from Professor Sir John Burn, Dr Katie Snape, and Drew Hyde, who lives with Lynch syndrome, as they reflect on decades of research, the importance of genetic diagnosis, and how a simple tablet could help prevent bowel cancer for future generations.

It's a fascinating conversation that reminds us that every advance in Lynch syndrome care begins with years of scientific research, and with patients and families choosing to take part.

Podcast Image for Podcast 'Could taking aspirin halve the risk of bowel cancer?

Key takeaways

Low-dose aspirin appears to reduce the risk of bowel cancer in people with Lynch syndrome by around 50%.
Lower doses appear to offer the same protection as higher doses, with fewer side effects.
The UK is the first country to recommend that people with Lynch syndrome are offered a discussion about aspirin as part of their care.
Around 90% of people with Lynch syndrome are still thought to be undiagnosed.
Prevention is becoming an increasingly important part of Lynch syndrome care, alongside surveillance and earlier diagnosis.
Aspirin is not suitable for everyone and should only be taken after discussing the benefits and risks with your healthcare team.

More than a research study

It's easy to see headlines about aspirin and think this is simply another medical study. But the podcast tells a much bigger story.

Professor Sir John Burn describes a journey spanning more than 40 years of research into inherited cancer, beginning long before Lynch syndrome was fully understood. Over those decades, researchers worked with families across the world to identify the genes responsible for the condition, understand how cancers develop, and investigate whether something as widely available as aspirin could reduce cancer risk.

The CaPP trials are a reminder that meaningful medical advances rarely happen overnight. They depend on years of collaboration between scientists, clinicians and, crucially, people living with Lynch syndrome who volunteer to take part in research.

The aspirin breakthrough

We've previously shared the detailed findings from the CaPP3 trial, but the podcast highlights why the results are so significant.

Earlier research from the CaPP2 study showed that people with Lynch syndrome taking 600 mg of aspirin each day developed around half as many bowel cancers as those who did not take aspirin. The obvious next question was whether a lower dose could provide the same protection. The answer appears to be yes.

CaPP3 found that lower doses produced similar protective benefits while reducing the likelihood of side effects associated with higher-dose aspirin. For many people, this means aspirin may become a more practical long-term option alongside regular colonoscopy surveillance.

The findings have already influenced clinical practice, with the UK becoming the first country to recommend that people with Lynch syndrome are offered a discussion about aspirin as part of their care.

Prevention takes patience

One of the most striking messages from the podcast is how long prevention research takes. Unlike treatments for existing cancer, prevention studies must often wait many years before researchers can see whether fewer cancers develop. Professor Burn explains that aspirin's protective effects only became fully apparent after many years of follow-up.

That long-term commitment, from both researchers and participants, is one of the reasons the evidence behind aspirin is now so compelling.

Drew's story reminds us why diagnosis matters

Alongside the science, the podcast features the personal experience of Drew Hyde, who was diagnosed with bowel cancer before discovering he had Lynch syndrome.

Like many people, Drew had no obvious family history that suggested an inherited cancer condition. It was only after his cancer diagnosis that genetic testing revealed the underlying cause. Following treatment, he joined regular surveillance and encouraged his children to undergo testing.

His reflections are a powerful reminder that knowing you have Lynch syndrome gives you choices. It opens the door to regular screening, conversations about aspirin, and informed decisions that may reduce future cancer risk.

The biggest challenge is finding the missing families

Perhaps the strongest message throughout the conversation is that the greatest challenge isn't developing new treatments, it's identifying the people who could benefit from them.

Professor Burn estimates that Lynch syndrome affects around 1 in 300 people, yet only around 10% are currently thought to know they have the condition.

That's just 1 in 10 people affected, meaning thousands of people across the UK may be living with Lynch syndrome without knowing they have an increased cancer risk or being offered surveillance and preventative options such as aspirin.

Encouragingly, routine testing of bowel cancers and endometrial cancers for Lynch syndrome is helping identify more families than ever before. But increasing awareness, among healthcare professionals and the public alike, remains essential.

Prevention is becoming a reality

The conversation also reflects on how much has changed in recent years. Not long ago, Lynch syndrome care focused primarily on detecting cancer early through surveillance. Today, that picture is evolving.

Alongside regular colonoscopies, there is now strong evidence supporting aspirin as a preventative option for many people. Research into LynchVax, a vaccine designed to prevent Lynch-associated cancers, is progressing into UK clinical trials. Advances in immunotherapy are also improving outcomes for people who do develop cancer.

Taken together, these developments show how rapidly Lynch syndrome research is moving, from earlier diagnosis and better surveillance towards preventing cancers from developing in the first place.

What this means for our community

For people living with Lynch syndrome today, this is an encouraging moment.

No single breakthrough will eliminate cancer risk overnight. Colonoscopy surveillance remains essential, and aspirin is not appropriate for everyone. Decisions about taking aspirin should always be made with your GP or specialist after considering your individual medical history. But this podcast demonstrates just how far research has come.

Every advance in Lynch syndrome care has been built on partnerships between researchers, clinicians and the Lynch syndrome community. The CaPP trials have already changed international guidance, and future research, including LynchVax, continues to build on that foundation.

There is still work to do, particularly in identifying the many people who remain undiagnosed. But there is also real reason for optimism.

Listen to the full conversation

If you'd like to hear Professor Sir John Burn, Dr Katie Snape and Drew Hyde discuss the research in more detail, you can listen to the full Behind the Genes podcast from Genomics England below:

Could taking aspirin halve the risk of bowel cancer?